media – Page 92 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Lilly joins fellow pharma giants in OpenAI partnership

Eli Lilly has joined a growing list of pharma companies to partner with OpenAI, as it seeks to develop new treatments for drug-resistant pathogens. The collaboration will utilise the generative artificial intelligence (genAI) from OpenAI to come up with new solutions for microbial infections. Lilly didn’t specify the exact details of how OpenAI’s technology will be used, or any financial terms of the deal. Lilly joins Sanofi and Moderna, who have both unveiled partnerships with the genAI platform OpenAI this year. Last month, Sanofi announced that it was partnering with Formation Bio and OpenAI to harness AI to expedite drug development. On the other hand, Moderna has incorporated ChatGPT into an internal messaging platform called mChat, to harness data analytics, and use image generation, and dose selection. This new collaboration with OpenAI builds on Lilly’s commitment to tackle antimicrobial resistance (AMR). The pharma giant previously contributed $100m to the AMR ...
- Source: drugdu
- 107
- June 28, 2024
GLP-1 shortages are not expected to resolve this year, says EMA Director

The glucagon-like peptide 1 (GLP-1) receptor agonists have emerged as blockbuster drugs and have raked in billions in sales. However, the higher demand for these therapies has now led to multiple reports of shortages. In response to these events, the European Medicines Agency (EMA) has put forth recommendations to tackle the shortages of these GLP-1 receptor agonists like Eli Lilly’s Trulicity (dulaglutide), and Novo Nordisk’s Ozempic (semaglutide), Saxenda (liraglutide) and Victoza (liraglutide). Another version of semaglutide, marketed as Wegovy, and Eli Lilly’s Mounjaro (tirzepatide) are approved in the EU for weight management in addition to diet and physical activity. The EMA has recommended that manufacturers and distributors avoid promotional activities for these products until the shortage persists. Cooke noted that EU member states should preserve stock, by controlling/limiting prescriptions. Broich stated that physicians should avoid prescribing GLP-1 receptor agonists for cosmetic use or in obese patients without any co-morbidities or ...
- Source: drugdu
- 87
- June 28, 2024
Chen Jining, Secretary of Shanghai Municipal Party Committee, met with Paul Han, CEO of French Sanofi Group

Chen Jining, Secretary of the Municipal Party Committee of Shanghai Municipality, met with Paul Han, CEO of Sanofi Group of France, and his delegation on the morning of June 26th. Chen Jining said that biomedicine is one of the three leading industries that Shanghai focuses on. We actively play the role of reform and opening up the test bed, around basic research, clinical trials, approval and supervision, health insurance, introduced a series of early and pilot implementation of policies and initiatives, to more competitive innovation advantages, industrial advantages, market advantages and comprehensive cost advantages, the whole chain to promote biomedical science and technology innovation and industrial development, and effectively promote people’s health and well-being. Sanofi is a leading global pharmaceutical and healthcare enterprise, welcome to grasp the opportunity of Shanghai’s industrial transformation, further increase the investment layout in Shanghai, and put more innovative R&D and manufacturing in Shanghai. We will ...
- Source: drugdu
- 96
- June 28, 2024
TOFIDENCE (BAT1806/BIIB800), a biosimilar developed by BIO-THERA with reference to Amero® (tolizumab), received marketing approval from the European Commission.

BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company is focused on developing a new generation of innovative drugs and biosimilars for the treatment of oncology, autoimmune diseases, cardiovascular diseases, ophthalmology and other major diseases that threaten human life or health. The Company’s partner, Bojian (NASDAQ: BIIB), recently received notification from the European Commission that it has granted marketing approval to BIO-THERA for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and other diseases. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in April 2024 for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. The European Commission’s approval of the marketing application for TOFIDENCE (BAT1806/BIIB800) ...
- Source: drugdu
- 63
- June 28, 2024
Health Asia

Organiser：Ecommerce Gateway Pakistan (Pvt.) Ltd Time：October 17-19, 2024 Address：Karachi Expo Center, University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Supplies: Medical diagnostic equipment, pharmaceuticals, electronic medical equipment and instruments, rescue equipment, medical reagent equipment, disposable medical equipment. Hospital Supplies: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical medical instruments, medical clothing and bedding, hospital furniture, emergency equipment, maternal and child care equipment, sterilization equipment, orthopedic prostheses, air filtration devices, blood pressure diagnostic instruments, heart rate monitors, ultrasound equipment, X-ray diagnostic equipment, urology and transplantation services, dialysis machines, physical therapy equipment. Laboratory Equipment: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, quality inspection equipment, laboratory renovation and upgrading technology, consumables, and related software. Pharmaceutical and Healthcare: Ophthalmology drugs, orthopedic drugs, traditional Chinese medicine, western medicine, traditional Chinese medicine health care drugs, nutritious foods, pharmaceutical intermediates, ...
- Source: drugdu
- 155
- June 28, 2024
【EXPERT Q&A】Is it easy to apply for the EU CE certification?

Drugdu.com expert’s response: CE certification is a certification system established by the European Union to ensure the safety of products for people, animals, and objects. For companies that want to export their products to EU member states, CE certification is essential. From a process perspective, CE certification is not complicated, mainly including filling out an application form, providing product information, sending samples for testing, and obtaining a certificate or report after passing the test. The entire process is usually completed within 5-7 working days. Therefore, from an operational level, CE certification is relatively easy to apply for. However, it should be noted that the preparation of technical documents involved in CE certification is relatively cumbersome, including but not limited to the product name, model, instruction manual, safety design documents, technical conditions, electrical schematics, etc. Enterprises need to ensure that these documents are complete, accurate, and comply with relevant EU standards.
- Source: drugdu
- 93
- June 28, 2024
New Urine Test Improves Accuracy for Early Detection of Bladder Cancer in Patients with Hematuria

Blood in the urine, known as hematuria, is often one of the earliest signs of bladder cancer. Although cystoscopy is recommended for patients presenting with both microscopic and gross hematuria, the detection rate for bladder cancer in these patients varies widely from 2% to 20%, leading to many unnecessary procedures. Additionally, due to the invasive nature of cystoscopy and low patient compliance, many cases of hematuria, especially microhematuria, are not promptly examined, missing early detection opportunities. This often results in diagnoses at more advanced stages, increasing both physical and economic burdens. To address these challenges, researchers have developed a simplified DNA-based urine test to enhance the early detection accuracy of bladder cancer in patients with hematuria and reduce reliance on more invasive cystoscopies. The potential of aberrant DNA methylation as a diagnostic biomarker for various cancers, including bladder cancer, has been recognized for some time. Researchers from Genomictree, Inc. (Daejeon, ...
- Source: drugdu
- 123
- June 27, 2024
Customizable AI Tool Helps Pathologists Identify Diseased Cells

Pathologists are tasked with examining body fluids or tissues to diagnose diseases, a process that involves distinguishing rare disease-indicating cells from thousands of normal cells under a microscope. This skill requires extensive training. Artificial intelligence (AI) can assist by learning to differentiate between healthy and diseased cells from digital pathology images. However, traditional AI tools, once trained, lack flexibility. They are designed for specific tasks, such as identifying cancer cells in one organ but not another, and might not align perfectly with a pathologist’s specific needs in different scenarios. Now, a collaborative team of computer scientists and physicians has developed a new AI tool that not only identifies diseased cells but also adapts to a pathologist’s requirements. Developed at Stanford Medicine (Stanford, CA, USA), the tool, named nuclei.io, functions like a human assistant that evolves with feedback. Starting with the basic function of recognizing different cell types by their nuclei, ...
- Source: drugdu
- 144
- June 27, 2024
FDA Accepts Otsuka and Lundbeck’s Supplemental New Drug Application for Brexpiprazole to Treat Adults with Post-Traumatic Stress Disorder

Don Tracy, Associate Editor Results from three randomized clinical trials show safety and efficacy of a brexpiprazole-sertraline combination in adult patients with post-traumatic stress disorder. The FDA has accepted Otsuka and Lunbdeck’s supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD). The sNDA is supported by data from three randomized clinical trials that evaluated the safety and efficacy of the brexpiprazole-sertraline combination in adult patients with PTSD.1 “[PTSD] is one of the most common mental health disorders in the United States. Approximately 13 million adults in the US have PTSD during a given year, and between seven to eight out of every 100 will experience PTSD at some point in their lives,” said John Kraus, MD, PhD, EVP, chief medical officer, Otsuka, in a press release. “This is a significant development, and we look forward to continuing our efforts ...
- Source: drugdu
- 119
- June 27, 2024
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease

The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank Vinluan A Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
- Source: drugdu
- 104
- June 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.